Barinthus Biotherapeutics plc American Depositary Shares (BRNS)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style balance-sheet investor and a Buffett-style business investor. Barinthus is a clinical-stage biotech with two main candidates: VTP-1000 in Phase I for celiac disease and VTP-300 in Phase II for chronic hepatitis. It has 14 employees and a $26.7M market cap, and the supplied data show no revenue growth figure, so there is no demonstrated commercial engine. I see no visible moat; the value, if any, rests on clinical trial outcomes rather than durable competitive advantage. Financial health is poor. Trailing free cash flow is -$26.4M, which is a -98.9% FCF yield against the $26.7M market cap, meaning the company burns nearly its entire market value annually. A Piotroski score of 1/9 and an Altman Z-score of -4.07 point to distress. ROE is -52.38% and ROCE is -18.99%, showing capital destruction. Debt/equity of 0.18 is not alarming by itself, but cash burn dominates. At the 2026-09-18 close, the P/E is -0.73 and P/B is 0.53, so the price is below FairStock's calculated book value. In biotech, book value can be impaired by trial setbacks. The company has only 0 years of filed annual results, so FairStock assigns no Lynch category, and I have no three-year record to judge. The beta of -0.36 is unusual but not a substitute for fundamental safety. Growth depends entirely on clinical readouts and financing. This is not a proven compounder; it is an option on science. At 0.53 times book it may screen cheap, but the burn and weak scores suggest the cheapness is a warning, not a margin of safety.

In plain English: Barinthus Biotherapeutics is a small healthcare company working on experimental immune treatments and vaccines, including one for celiac disease and one for chronic hepatitis. The business looks weak today: it is not producing meaningful revenue, is burning cash, and has very little financial cushion. The price may look low compared with its stated accounting value, but the numbers show a speculative, early-stage company rather than a proven bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-18 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer